Identifiez-vous pour voir le profil complet de Daniel-Isui
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Paris, Île-de-France, France
Coordonnées
Identifiez-vous pour voir le profil complet de Daniel-Isui
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
662 abonnés
+ de 500 relations
Identifiez-vous pour voir le profil complet de Daniel-Isui
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Voir les relations en commun avec Daniel-Isui
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Voir les relations en commun avec Daniel-Isui
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Identifiez-vous pour voir le profil complet de Daniel-Isui
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Activité
Identifiez-vous pour voir le profil complet de Daniel-Isui
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
-
Paris-based Samp develops AI-supported digital twin solutions to facilitate the monitoring and management of industrial areas. The startup increases…
Paris-based Samp develops AI-supported digital twin solutions to facilitate the monitoring and management of industrial areas. The startup increases…
Aimé par Daniel-Isui Aguilar-Salvador
-
I am happy to announce that our latest article on membrane based fermentation is now published on the Chemical Engineering Journal. The work was…
I am happy to announce that our latest article on membrane based fermentation is now published on the Chemical Engineering Journal. The work was…
Aimé par Daniel-Isui Aguilar-Salvador
-
On monday I had the pleasure to give a seminar at the french Saint-Gobain research facility about biomineralization for climate tech, and obviously…
On monday I had the pleasure to give a seminar at the french Saint-Gobain research facility about biomineralization for climate tech, and obviously…
Aimé par Daniel-Isui Aguilar-Salvador
Expérience et formation
-
Marble
******* ** *********
-
******* *******
**-*******
-
********
****** *******
-
***** ******* ***é******
****** * (**) ********
-
-
*********é ***** *******
-
-
Voir toute l’expérience de Daniel-Isui
Découvrez son poste, son ancienneté et plus encore.
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Langues
-
Spanish
-
-
English
-
-
French
-
Plus d’activités de Daniel-Isui
-
💧 Seawater and brine may seem unusable, but they hold incredible potential! 💡 Unlike freshwater sources, they're not ideal for irrigation or…
💧 Seawater and brine may seem unusable, but they hold incredible potential! 💡 Unlike freshwater sources, they're not ideal for irrigation or…
Aimé par Daniel-Isui Aguilar-Salvador
-
Nos co-fondateurs, Paul Malfoy et Valentin SABATET font partie de Forbes 30 under 30 EUROPE ! Dans la catégorie “Manufacturing & Industry” ! Le…
Nos co-fondateurs, Paul Malfoy et Valentin SABATET font partie de Forbes 30 under 30 EUROPE ! Dans la catégorie “Manufacturing & Industry” ! Le…
Aimé par Daniel-Isui Aguilar-Salvador
Voir le profil complet de Daniel-Isui
S’identifier
Tenez-vous au courant des évolutions de votre monde professionnel
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Autres profils similaires
-
Albin Salazar
Researcher in computer science and life sciences.
ConstanceSe connecter -
Youcef Akrout
ParisSe connecter -
Joana Treger
Docteure en mathématiques spécialiste en cryptologie • UI, UX • Design et programmation web • Architecture de contenus • Gestion de projets
Parati, RJSe connecter -
Emeric de Waziers
Paris et périphérieSe connecter -
Pierre-Yves Cointot
Cinquième année d’ostéopathie
Paris et périphérieSe connecter -
Juan García Ruiz
PhD candidate
BordeauxSe connecter -
Ninna Granucci
Co-founder and President at Green Spot Technologies// Helping food companies leverage cocoa alternatives
ToulouseSe connecter -
Gérald Lelong
Directeur Général @ Easymov Robotics
Clermont-FerrandSe connecter -
Marion Tanguy
FranceSe connecter -
Sawsen Rezig
ParisSe connecter -
Mehdi Safraoui
Senior Consultant chez SMART CONSULTING SAS
Paris et périphérieSe connecter -
Marco Liuni
Sound | R&D | Product
MeudonSe connecter -
Yvonne Duval
Co-Founder at Nam Sustineri Terrae
AntibesSe connecter -
Niccolo Somaschi
MassySe connecter -
Yves Soufflet
Co-founder of Waves'nSee
Toulouse et périphérieSe connecter -
Pierre Rouanet
Bordeaux et périphérieSe connecter -
Jean-Bastien Dussart
SciencePo | Mines - Renewable Energies - Startup founder
ParisSe connecter -
Khalil Hammami
Research and Development Engineer at Inria
Lille et périphérieSe connecter -
Alexandre Fabry
Co-founder @The Bridge Gallery | Contemporary art from Africa and its diaspora
ParisSe connecter -
Lucas Fernández Brillet
Co-Founder, AI lead @ StockFink, PhD Deep Learning, Engineer
EspagneSe connecter
Découvrir plus de posts
-
World Scientific Publishing
This review by Dr Olalla Castro-Alvaredo (University of London) and Lucia Santamaria-Sanz (Universidad de Burgos) explores the definitions, ideas, and techniques for symmetry-resolved entanglement measures, focusing on symmetry-resolved entanglement entropy in quantum field theories with internal symmetry, specifically in conformal and integrable quantum field theories using (composite) branch point twist fields. 📚Read the paper here: https://lnkd.in/grv5Q8JN #entanglemententropy #quantumfieldtheory #twistfields #integrability
1 -
es/iode
📃Scientific paper: Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort Abstract: BACKGROUND: Predicting prognosis in Parkinson's disease (PD) has important implications for individual prognostication and clinical trials design and targeting novel treatments. Blood biomarkers could help in this endeavor. METHODS: We identified 4 blood biomarkers that might predict prognosis: apolipoprotein A1, C‐reactive protein, uric acid and vitamin D. These biomarkers were measured in baseline serum from 624 Parkinson's disease subjects (median disease duration, 1.0 years; interquartile range, 0.5–2.0) from the Oxford Discovery prospective cohort. We compared these biomarkers against PD subtypes derived from clinical features in the baseline cohort using data‐driven approaches. We used multilevel models with MDS‐UPDRS parts I, II, and III and Montreal Cognitive Assessment as outcomes to test whether the biomarkers predicted subsequent progression in motor and nonmotor domains. We compared the biomarkers against age of PD onset and age at diagnosis. The q value, a false‐discovery rate alternative to P values, was calculated as an adjustment for multiple comparisons. RESULTS: Apolipoprotein A1 and C‐reactive protein levels differed across our PD subtypes, with severe motor disease phenotype, poor psychological well‐being, and poor sleep subtype having reduced apolipoprotein A1 and higher C‐reactive protein levels. Reduced apolipoprotein A1, higher C‐reactive protein, and reduced vitamin D were associated with worse baseline activities of daily living (MDS‐UPDRS... Continued on ES/IODE ➡️ https://etcse.fr/F4KA ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
-
es/iode
📃Scientific paper: Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort Abstract: BACKGROUND: Predicting prognosis in Parkinson's disease (PD) has important implications for individual prognostication and clinical trials design and targeting novel treatments. Blood biomarkers could help in this endeavor. METHODS: We identified 4 blood biomarkers that might predict prognosis: apolipoprotein A1, C‐reactive protein, uric acid and vitamin D. These biomarkers were measured in baseline serum from 624 Parkinson's disease subjects (median disease duration, 1.0 years; interquartile range, 0.5–2.0) from the Oxford Discovery prospective cohort. We compared these biomarkers against PD subtypes derived from clinical features in the baseline cohort using data‐driven approaches. We used multilevel models with MDS‐UPDRS parts I, II, and III and Montreal Cognitive Assessment as outcomes to test whether the biomarkers predicted subsequent progression in motor and nonmotor domains. We compared the biomarkers against age of PD onset and age at diagnosis. The q value, a false‐discovery rate alternative to P values, was calculated as an adjustment for multiple comparisons. RESULTS: Apolipoprotein A1 and C‐reactive protein levels differed across our PD subtypes, with severe motor disease phenotype, poor psychological well‐being, and poor sleep subtype having reduced apolipoprotein A1 and higher C‐reactive protein levels. Reduced apolipoprotein A1, higher C‐reactive protein, and reduced vitamin D were associated with worse baseline activities of daily living (MDS‐UPDRS... Continued on ES/IODE ➡️ https://etcse.fr/F4KA ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
-
es/iode
📃Scientific paper: Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort Abstract: BACKGROUND: Predicting prognosis in Parkinson's disease (PD) has important implications for individual prognostication and clinical trials design and targeting novel treatments. Blood biomarkers could help in this endeavor. METHODS: We identified 4 blood biomarkers that might predict prognosis: apolipoprotein A1, C‐reactive protein, uric acid and vitamin D. These biomarkers were measured in baseline serum from 624 Parkinson's disease subjects (median disease duration, 1.0 years; interquartile range, 0.5–2.0) from the Oxford Discovery prospective cohort. We compared these biomarkers against PD subtypes derived from clinical features in the baseline cohort using data‐driven approaches. We used multilevel models with MDS‐UPDRS parts I, II, and III and Montreal Cognitive Assessment as outcomes to test whether the biomarkers predicted subsequent progression in motor and nonmotor domains. We compared the biomarkers against age of PD onset and age at diagnosis. The q value, a false‐discovery rate alternative to P values, was calculated as an adjustment for multiple comparisons. RESULTS: Apolipoprotein A1 and C‐reactive protein levels differed across our PD subtypes, with severe motor disease phenotype, poor psychological well‐being, and poor sleep subtype having reduced apolipoprotein A1 and higher C‐reactive protein levels. Reduced apolipoprotein A1, higher C‐reactive protein, and reduced vitamin D were associated with worse baseline activities of daily living (MDS‐UPDRS... Continued on ES/IODE ➡️ https://etcse.fr/F4KA ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
-
es/iode
📃Scientific paper: Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort Abstract: BACKGROUND: Predicting prognosis in Parkinson's disease (PD) has important implications for individual prognostication and clinical trials design and targeting novel treatments. Blood biomarkers could help in this endeavor. METHODS: We identified 4 blood biomarkers that might predict prognosis: apolipoprotein A1, C‐reactive protein, uric acid and vitamin D. These biomarkers were measured in baseline serum from 624 Parkinson's disease subjects (median disease duration, 1.0 years; interquartile range, 0.5–2.0) from the Oxford Discovery prospective cohort. We compared these biomarkers against PD subtypes derived from clinical features in the baseline cohort using data‐driven approaches. We used multilevel models with MDS‐UPDRS parts I, II, and III and Montreal Cognitive Assessment as outcomes to test whether the biomarkers predicted subsequent progression in motor and nonmotor domains. We compared the biomarkers against age of PD onset and age at diagnosis. The q value, a false‐discovery rate alternative to P values, was calculated as an adjustment for multiple comparisons. RESULTS: Apolipoprotein A1 and C‐reactive protein levels differed across our PD subtypes, with severe motor disease phenotype, poor psychological well‐being, and poor sleep subtype having reduced apolipoprotein A1 and higher C‐reactive protein levels. Reduced apolipoprotein A1, higher C‐reactive protein, and reduced vitamin D were associated with worse baseline activities of daily living (MDS‐UPDRS... Continued on ES/IODE ➡️ https://etcse.fr/F4KA ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
-
Spiritual Alchemy Foundation of Enlightenment Inc.
"US-2020279585-A1 Inventor: ROTHSCHILD RICHARD A (GB) Assignee: ROTHSCHILD RICHARD A (GB) CountryUnited States DatesPriority: 2015/10/13 DescriptionThis web page summarizes information in PubChem about patent US-2020279585-A1. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed, please visit the PubChem patents help page. NOTE: The priority date for patent application US-2020279585-A1 (and the corresponding grant US-11024339-B2) that Google has supplied is based on a series of separate-but-related patent applications dating back to 2015. Of those various applications, only US-2020279585-A1 mentions COVID-19, and it was filed on May 17, 2020. Please see the knowledgebase article on the topic: https://lnkd.in/dncQjE7C" (Ref link Below) ..Sometimes those who wear tin hats are not far off from the truth. Look at the names, dates, and sources (nih.gov) of the information. There is more evidence of a 'cabal' working for a globalized, socialist and communist world government than there is not. Wait until the circumstantial becomes the irrefutable, God willing it won'be too late then... #QuantumMinister System and Method for Testing for COVID-19 - Patent US-2020279585-A1 - PubChem (nih.gov)
-
Hello Bio
The intensity of research work brings with it a unique set of pressures, and the mental health of a working scientist can be stretched to the point of burnout. 🤯 In this new article, Dr Noelia Pilar Domínguez Falcón of the University of East Anglia explains why it’s important to share our personal experiences, and offers practical tips for managing stress and anxiety in the lab: https://ow.ly/1xwQ50Rzsmo #mentalhealth #stress #anxiety #STEMmentalhealth #supportforscientists #mentalhealthsupport #mentalhealthtips #PhDsupport #postdochelp
10 -
Geopolitical Intelligence Services
The grip left-wing radicals have on academia is already very strong and it is improbable that anything will change that. In this likely scenario, Western universities will continue to grow an unaccountable, unproductive left-wing “elite.” Read more in our newest report by Henrique Schneider: https://lnkd.in/d-5fu-xw
282 commentaires -
The Friedman Brain Institute
PRESS RELEASE | OUT NOW! Mount Sinai Study Reveals Significant Differences in RNA Editing Between Postmortem and Living Human Brain ➡️ https://lnkd.in/e-sSwGqF Miguel Rodriguez de los Santos, Brian Kopell, Ariela Buxbaum Grice, et al. from the Icahn School of Medicine at Mount Sinai have shed valuable light on the nuanced functions and intricate regulatory methods of RNA editing, a critical mechanism underlying brain development and disease. In this study, published in Nature Communications, the team reported finding major differences between postmortem and living prefrontal cortex brain tissues as they relate to one of the most abundant RNA modifications in the brain, known as adenosine-to-inosine (A-to-I) editing. This discovery will play a significant role in shaping the development of diagnostics and therapies for brain diseases. “We hypothesized that molecular responses to postmortem-induced hypoxic and immune responses can significantly alter the landscape of A-to-I editing. This can lead to misunderstandings about RNA editing in the brain if we only study postmortem tissues… Studying living brain tissue provides us with a clearer picture of RNA editing biology in the human brain.” - Dr. Miguel Rodríguez de los Santos “Utilizing fresh brain tissue from living human donors provided us the opportunity to investigate the brain without the confounds inherent to postmortem tissue analysis… In doing so, we revealed more accurate insights into the prevalence and roles of A-to-I editing in the human brain. It is critical to note that our findings do not negate but instead provide missing context for using postmortem brain tissues in researching A-to-I regulation. Understanding these differences helps improve our knowledge of brain function and disease through the lens of RNA editing modifications, which can potentially lead to better diagnostic and therapeutic approaches.” - Dr. Alexander Charney Learn More in Nature Communications | Nature Portfolio https://lnkd.in/ebvnQwCg Divergent landscapes of A-to-I editing in postmortem and living human brain - Miguel Rodriguez de los Santos, PhD; Brian Kopell, Ariela Buxbaum Grice, Panos Roussos, Alexander Charney, Michael S. Breen, PhD, et al. #FriedmanBrainInstitute #NashNeuroscience #LivingBrainProject The Mount Sinai Hospital Graduate School of Biomedical Sciences at the Icahn School of Medicine The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai
261 commentaire -
Institute for Manufacturing (IfM), University of Cambridge
💡 What is the strategy behind one of the world's most successful labs, the MRC Laboratory of Molecular Biology (LMB) in Cambridge? In a new article in Nature Magazine, Professor Chander Velu investigates this question from a management perspective in collaboration with Toni Vidal-Puig MD PhD FRCP FMedSci MBA and Luka Gebel. 🔎 They identify three key principles of integrated management at the LMB: 1️⃣ Great diversity of research fields within the lab; 2️⃣ A strong incentive structure which encourages fruitful forms of collaboration; 3️⃣ A highly effective management oversight system manages tensions between science and technology priorities. #sciencemanagement #technologymanagement #innovationmanagement
152 commentaires -
Phage Hunters Training and Research Program
𝗔𝗜 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲𝘀 𝗙𝗶𝗻𝗱𝗶𝗻𝗴 𝗕𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗽𝗵𝗮𝗴𝗲𝘀 Antibiotics are losing effectiveness against bacteria, posing a global health crisis. Bacteriophages offer a promising natural alternative, as they can target and kill specific bacteria. Nonetheless, identifying the right phage to combat a particular bacterial infection can be a time-consuming process. Researchers at Berkeley Lab are addressing this challenge by harnessing the power of artificial intelligence (AI). They have developed a machine learning model called 𝗣𝗵𝗮𝗴𝗲𝗛𝗼𝘀𝘁𝗟𝗲𝗮𝗿𝗻, which can predict which phages are likely to infect Klebsiella bacteria, a common cause of hospital-acquired infections. Dr. Dimitri Boeckaerts, a computational biologist at Berkeley Lab and the lead author of the study, emphasizes the immense potential of phage therapy and the impact of their AI model in expediting the process of finding effective phages. 𝗛𝗼𝘄 𝗣𝗵𝗮𝗴𝗲𝗛𝗼𝘀𝘁𝗟𝗲𝗮𝗿𝗻 𝗪𝗼𝗿𝗸𝘀 PhageHostLearn is trained on a large dataset of known phage-bacteria interactions. It analyzes the proteins on the surface of both the phage and bacteria, focusing on the initial step where the phage attaches to the bacterial host. Through understanding these protein interactions, PhageHostLearn can predict whether a specific phage is likely to infect a particular bacterial strain. The model then identifies and prioritizes phages for further testing in the lab, saving significant time and resources. Dr. Boeckaerts notes that the model has shown a hit rate of around 65% to 84%, signifying a significant improvement over traditional screening methods. 𝗧𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 While PhageHostLearn is a significant step forward, the researchers acknowledge that further work is needed. The model is currently effective for Klebsiella bacteria, but the development of similar models for other common bacterial pathogens is essential. Additionally, expanding the available data on phage-host interactions is crucial for the continued development and refinement of AI models. Dr. Boeckaerts concludes with optimism, believing that AI has the potential to transform phage therapy. He highlights the importance of combining advanced machine learning with the power of natural viruses in our fight against antibiotic resistance and in revolutionizing the treatment of bacterial infections. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲:-https://shorturl.at/KVLsB https://shorturl.at/anyQ4 Summarized by: Alice Auko Owiti #phagetherapy #antibioticresistance #bacteriophages #AI #machinelearning #healthcare #research #phagehostinteraction #computationalbiology #antimicrobialresistance #drugdiscovery #bacteriako #futureofmedicine
988 commentaires -
University of Cambridge
👁️ AI is much better than non-specialist doctors at assessing eye problems and providing advice, Cambridge researchers have found. GPT-4 could triage patients and decide which ophthalmology issues are emergencies that need immediate attention. It could also be useful for providing eye-related advice, diagnosis, and management suggestions in places where access to specialist healthcare professionals is limited. The researchers, led by Arun Thirunavukarasu, say that large language models aren’t likely to replace healthcare professionals, but have the potential to improve healthcare. #AI #Opthamology #GPT4 #Cambridge #CambridgeUniversity #UniversityOfCambridge
30713 commentaires -
International Development Research Centre (IDRC)
The global research funding landscape needs transformation, and it starts with strengthening southern granting councils. Let's shift the paradigm and ensure equitable access to resources for impactful science and innovation. Explore how we’re working with national science granting councils by following the link in the comments! Secretaría Nacional de Ciencia, Tecnología e Innovación ANII CONICET Dialoga #INGSA2024 #decolonization
91 commentaire -
Biomimicry Works
Our first Biomimicry Works podcast 🎉 Peter Philips and Dr Nicolene share their journey in creating Biomimicry Works and deeper insights into who they are, and why they create in the ways they do Here's what we uncover: ↳ The essence of Biomimicry Works: It's more than a business, we are Custodians of a movement. ↳ The power of storytelling: How sharing personal experiences unlocks the true potential of biomimicry. ↳ Building a thriving community: Fostering collaboration, communication, and a space for diverse perspectives. ↳ Exploring the "warm data" concept: Exploring the space between biomimicry and other interconnected fields. ↳ Leading through creation: Embracing the unknown and leading the way for others to gain courage and share Click below to watch & make sure you SUBSCRIBE to the Symbiotic Future YouTube Channel where our videos are hosted Let us know your feedback in the comments once you've watched Make sure you, like, comment and repost! 👍🏽 💬 ♻️ https://lnkd.in/g72iAJBy
7 -
UNU-WIDER - United Nations University World Institute for Development Economics Research
Extractive industries help combat energy poverty, but what are 6 main dilemmas arising from their increasing importance for Global South economies? This new working paper by Tony Addison and Alan Roe helps policymakers in their hard choices: https://go.unu.edu/qm3Tr #E4D #DRMprogramme
3 -
UNU-WIDER - United Nations University World Institute for Development Economics Research
Extractive industries help combat energy poverty, but what are 6 main dilemmas arising from their increasing importance for Global South economies? This new working paper by Tony Addison and Alan Roe helps policymakers in their hard choices: https://go.unu.edu/qm3Tr #E4D #DRMprogramme
9 -
Innovation News Network
Scientists at the University of Cambridge have pioneered an economical and efficient method for creating materials for CO2 capture. The innovative CO2 capture method is similar to charging a battery, but instead charges activated charcoal, commonly used in household water filters. Charging the charcoal 'sponge' with ions forms reversible bonds with CO2 that effectively capture the CO2 from the air. #CarbonCapture #AirPollution #NetZeto #CarbonEmissions #GreenhouseGases https://bit.ly/45exsc9
2 -
ISISE - Institute for Sustainability and Innovation in Structural Engineering
#tbt 🌐 ISISE - Participation in an International Workshop 🌐 𝐌𝐈𝐓 𝐏𝐨𝐫𝐭𝐮𝐠𝐚𝐥 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐖𝐨𝐫𝐤𝐬𝐡𝐨𝐩 𝟐𝟎𝟐𝟒 📌 Location: Massachusetts Institute of Technology (MIT), Boston, USA 📅 Date: 3 - 7 June 2024 👩🎓 👨🎓 PhD students: Denner Déda, Adriana Salles, Camila Cervantes, and Estefania Cervantes. 💡 About the Workshop This workshop is promoted by the MIT Portugal program. This year brought together 35 students from various Portuguese universities, the team had the incredible opportunity to present their innovative ideas for sustainability in the construction sector, bridges and ESG management software. The event was also attended by Fernando Alexandre, Portugal's Minister for Education, Science and Innovation, who had a chat session with the students. 🚀 Main highlights: ✅ Discussed de-risking, market fit, and financing strategies with world-renowned professors and entrepreneurs. ✅Gaining valuable insights from the world-leading innovation ecosystem at MIT. ✅Networking with peers and experts who are passionate about sustainability and innovation. ✅ Students dedicated a week to preparing and planning their entrepreneurial ideas, returned from the workshop not only inspired but also equipped with new knowledge and insights. ✅This experience furthered our mission of advancing sustainable engineering solutions, and we look forward to the potential impact of their learnings on future projects. ➕ Find more about this event: https://buff.ly/4bXcSQe #ISISE #FP #Scon #Ucoimbra #UMInho #MITPortugal #Innovation #sustainability #Sustainableconstruction #entrepreneurship
112 -
Sustainable Tech Partner
Updated list: 54 technology accelerators for #sustainability, #GreenIT and #ClimateTech #startups. The latest addition to the list is the Sustainability Accelerator at the Stanford Doerr School of Sustainability -- which will target five markets: (1) climate adaptation, (2) food and agriculture, (3) water, (4) electricity and grid systems, and (5) industry. If you are an #entrepreneur building a sustainability #startup that needs business, technology or financial guidance, check out the entire list here: https://lnkd.in/eT5PDC86 #Upstart #Funding #Mentoring #Incubators
3 -
The Yuan
A cancer cure once seemed like an ambitious yet distant dream. However, companies like Oxford Drug Design are transforming this dream into reality. The Yuan contributor, Oladimeji Ewumi, explores this exciting development in a recent interview with Alan D. Roth, the CEO of Oxford Drug Design, revealing how the landscape is changing for the better. #GrahamRichards #OxfordUniversity # CancerResearchUKScotlandInstitute #SynthAI platform https://lnkd.in/gtQfg4xn
2